Unknown Unknown
Unknown (Nasdaq: Unknown) is an oncology drug developer. Its lead program, atebimetinib (IMM-1-104), is in Phase 3 for first-line metastatic pancreatic ductal adenocarcinoma (PDAC).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| atebimetinib (IMM-1-104) | first-line metastatic PDAC | small molecule | Phase 3 |
| envometinib (IMM-6-415) | advanced solid tumors | small molecule | Pre-clinical |
Recent results and decisions
- Jun 1, 2026positive Atebimetinib plus mGnP demonstrated 17.3 month median overall survival in 55 first-line pancreatic cancer patients in Phase 2a trial, presented at ASCO.
17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported in oral presentation at ASCO Annual Meeting on June 1
Filing - Jun 1, 2026started MAPKeeper 301 pivotal Phase 3 trial of atebimetinib plus mGnP in first-line metastatic pancreatic cancer has dosed its first patient.
In June, Immuneering announced it had dosed the first patient in MAPKeeper 301, a global, randomized, open-label pivotal Phase 3 clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer patients.
Filing - Jun 1, 2026n/a Andrew Gengos appointed Chief Financial Officer.
In June, Immuneering announced the appointment of Andrew Gengos as Chief Financial Officer.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.